Notch2, a Key Player in Chronic Lymphocytic Leukemia: Mechanism, Microenvironment Interactions, and Therapeutic...

Area of Science:

• Hematology
• Cancer Biology
• Molecular Oncology

Background:

• Tissue niches, including spleen and bone marrow, are vital for chronic lymphocytic leukemia (CLL) cell survival and growth.
• The tumor microenvironment (TME) significantly influences CLL pathophysiology, development, and treatment resistance.
• Leukemic cells in CLL exhibit aberrant Jagged1/2 ligand expression, activating Notch2 signaling.

Purpose of the Study:

• To investigate the role of Notch2 signaling in the CLL tumor microenvironment.
• To elucidate the mechanisms by which Notch2 contributes to CLL cell survival and drug resistance.
• To identify potential therapeutic targets within the Notch2 signaling pathway in CLL.

Main Methods:

• Analysis of Notch2 activation in CLL cells and stromal cells.
• Investigation of Jagged1/2 ligand expression in leukemic cells.
• Assessment of Notch2's downstream effects on Wnt/β-catenin and Mcl-1 expression.
• Evaluation of Notch2's role as a transcription factor for CD23 and Hes1.

Main Results:

• Notch2 is functionally activated in CLL, independent of mutations, via Jagged1/2 ligand expression.
• Notch2 activation on stromal cells triggers the Wnt/β-catenin pathway in CLL cells.
• Notch2 activation in CLL cells upregulates Mcl-1, conferring drug tolerance, particularly in trisomy 12 cases.
• Notch2 directly regulates CD23 and Hes1 expression, crucial for CLL cell proliferation and survival.

Conclusions:

• Notch2 signaling pathways are critical for CLL cell dependence on their niche.
• These pathways contribute to the formation of proliferation centers in CLL.
• Notch2-mediated circuits represent key therapeutic targets for overcoming treatment resistance in CLL.